Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: A randomized controlled trial

American Journal of Clinical Nutrition

Volumn 97, Issue 6, 2013, Pages 1201-1209

  Neufingerl, Nicole ^a   Zebregs, Yvonne E M P ^a   Schuring, Ewoud A H ^a   Trautwein, Elke A ^a  

^a UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTICOA; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CAFFEINE; FLAVONOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; THEOBROMINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CACAO; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

THEOBROMA CACAO;

EID: 84878379714     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.047373     Document Type: Article

References (44)

1. Buitrago-Lopea A, Sanderson J, Johnson L, Warnakula S, Wood A, Franco OH. Chocolate consumption and cariometabolic disorders: systematic review and meta-analysis. BMJ 2011;343:d4488.
2. Ried K, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A meta-analysis. BMC Med 2010;8:8.
3. Ding EL, Hutfless SM, Ding X, Girotra S. Chocolate and prevention of cardiovascular disease: a systematic review. Nutr Metab (Lond) 2006;3:2.
4. Fernández-Murga L, Tarin JJ, Garcia-Perez MA, Cano A. The impact of chocolate on cardiovascular health. Maturitas 2011;69:312-21.
5. Jia L, Liu XA, Bai YY, Li SH, Sun K, He C, Hui RT. Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2010;92:218-25.
6. Shrime MG, Bauer SR, McDonald AC, Chowdhury NH, Coltart CEM, Ding EL. Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. J Nutr 2011;141:1982-8.
7. Tokede OA, Gaziano JM, Djousse L. Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur J Clin Nutr 2011;65:879-86.
8. Baba S, Osakabe N, Kato Y, Natsume M, Yasuda A, Kido T, Fukuda K, Muto Y, Kondo K. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans'. Am J Clin Nutr 2007;85:709-17. (Pubitemid 46393501)
9. Khan N, Monagas M, Andres-Lacueva C, Casas R, Urpy{combining double acute accent}-Sarda M, Lamuela-Raventos RM, Estruch R. Regular consumption of cocoa powder with milk increases HDL cholesterol and reduces oxidized LDL levels in subjects at high-risk of cardiovascular disease. Nutr Metab Cardiovasc Dis 2012;22:1046-53.
10. Kris-Etherton PM, Derr JA, Mustad VA, Seligson FH, Pearson TA. Effects of a milk chocolate bar per day substituted for a high-carbohydrate snack in young men on an NCEP/AHA Step 1 Diet. Am J Clin Nutr 1994;60(6 suppl):1037S-42S.
11. Mellor DD, Sathyapalan T, Kilpatrick ES, Beckett S, Atkin SL. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in type 2 diabetes patients. Diabet Med 2010;27:1318-21.
12. Mursu J, Voutilainen S, Nurmi T, Rissanen TH, Virtanen JK, Kaikkonen J, Nyyssoonen K, Salonen JT. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic Biol Med 2004;37:1351-9.
13. Wang-Polagruto JF, Villablanca AC, Polagruto JA, Lee L, Holt RR, Schrader HR, Ensunsa JL, Steinberg FM, Schmitz HH, Keen CL. Chronic consumption of flavanol-rich cocoa improves endothelial function and decreases vascular cell adhesion molecule in hype cholesterolemic postmenopausal women. J Cardiovasc Pharmacol 2006;47:S177-86. (Pubitemid 44620209)
14. Balzer J, Rassaf T, Heiss C, Kleinbongard P, Lauer T, Merx M, Heussen N, Gross HB, Keen CL, Schroeter H, et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients - a double-masked, randomized, controlled trial. J Am Coll Cardiol 2008;51:2141-9. (Pubitemid 351713684)
15. Crews WD, Harrison DW, Wright JW. A double-blind, placebo-controlled, randomized trial of the effects of dark chocolate and cocoa on variables associated with neuropsychological functioning and cardiovascular health: clinical findings from a sample of healthy, cognitively intact older adults. Am J Clin Nutr 2008;87:872-80. (Pubitemid 351549231)
16. Davison K, Coate AM, Buckley JD, Howe PRC. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Int J Obes (Lond) 2008;32:1289-96.
17. Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, Kwak HK, Milbury P, Paul SM, Blumberg J, et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr 2004;23:197-204. (Pubitemid 38746107)
18. Muniyappa R, Hall G, Kolodziej TL, Karne RJ, Crandon SK, Quon MJ. Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension. Am J Clin Nutr 2008;88:1685-96.
19. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide - a randomized controlled trial. JAMA 2007;298:49-60. (Pubitemid 47026770)
20. Wan Y, Vinson JA, Etherton TD, Proch J, Lazarus SA, Kris-Etherton P. Effects of cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in humans. Am J Clin Nutr 2001;74:596-602. (Pubitemid 33015145)
21. NCEP Expert panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
22. Galleano M, Oteiza PI, Fraga CG. Cocoa, chocolate, and cardiovascular disease. J Cardiovasc Pharmacol 2009;54:483-90.
23. Huxley RR, Neil HAW. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 2003;57:904-8. (Pubitemid 36987238)
24. Riksen NP, Smits P, Rongen GA. The cardiovascular effecs of methylxanthines. In: Fredholm BB, ed. Methylxanthines. Heidelberg, Germany: Springer Verlag Berlin, 2011:413-37.
25. Smit HJ. Theobromine and the pharmacology of cocoa. In: Fredholm BB, ed. Methylxanthines. Heidelberg, Germany: Springer Verlag Berlin, 2011:201-34.
26. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik G, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(suppl 2):S1-113.
27. Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Oxidants and Antioxidants Pt A 1999;299:152-78. (Pubitemid 28483890)
28. Ptolemy AS, Tzioumis E, Thomke A, Rifai S, Kellogg M. Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: a single analytical protocol applicable to cocoa intervention studies. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:409-16.
29. Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl 2005;7:L21-6. (Pubitemid 41630388)
30. Fraga CG, Actis-Goretta L, Ottaviani JI, Carrasquedo F, Lotito SB, Lazarus S, Schmitz HH, Keen CL. Regular consumption of a flavanolrich chocolate can improve oxidant stress in young soccer players. Clin Dev Immunol 2005;12:11-7. (Pubitemid 41647025)
31. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 2005;81:611-4.
32. Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005;46:398-405. (Pubitemid 41099176)
33. Osakabe N, Baba S, Yasuda A, Iwamoto T, Kamiyama M, Tokunaga T, Kondo K. Dose-response study of daily cocoa intake on the oxadative susceptibility of low-density lipoprotein in healthy human volunteers. J Health Sci 2004;50:679-84. (Pubitemid 41295284)
34. Bruckert E. Epidemiology of low HDL-cholesterol: results of studies and surveys. Eur Heart J Suppl 2006;8:F17-22. (Pubitemid 44453611)
35. Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, Suzuki E, Shimano H, Yamamoto S, Kondo K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol - a meta-analysis. Arch Intern Med 2007;167:999-1008. (Pubitemid 46835787)
36. Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, Dubose KD. Blood lipid and lipoprotein adaptations to exercise - a quantitative analysis. Sports Med 2001;31:1033-62. (Pubitemid 34017009)
37. Katcher HI, Hill AM, Lanford JLG, Yoo JS, Kris-Etherton PM. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am 2009;38:45.
38. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobus DR, Bangdivala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15. (Pubitemid 19043669)
39. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97. (Pubitemid 40094724)
40. Bhatt KN, Wells BJ, Sperling LS, Baer JT. High-density lipoprotein therapy: is there hope? Curr Treat Options Cardiovasc Med 2010;12:315-28.
41. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K.
42. Abbott RD, Wilson PWF, Kannel WB, Castelli WP. High-density lipoprotein cholesterol, total cholesterol screening, and myocardial-infarction - the Framingham-Study. Arteriosclerosis 1988;8:207-11.
43. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. (Pubitemid 28213628)
44. NEVO Foundation. Dutch food composition table 2001. The Hague, Netherlands: PlantijnCasparie, 2011.